Skip to main content
HR 6574 115th Congress House

Medicare Fair Drug Pricing Act of 2018

Official title: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to determine, on behalf of Medicare beneficiari… Show full official titleShow less

Official title: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to determine, on behalf of Medicare beneficiaries, covered part D drug prices for certain covered part D drugs, and for other purposes.

Introduced: July 26, 2018 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
Health Congressional oversightGovernment studies and investigationsHealth care coverage and accessMedicarePrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 13, 2018
Referred to the Subcommittee on Health.
Jul 27, 2018
Referred to the Subcommittee on Health.
Jul 26, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 26, 2018
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action August 13, 2018

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Medicare Fair Drug Pricing Act of 2018

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.

Under current law, the CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. The CMS must promulgate regulations regarding the identification of such drugs.

With respect to these drugs, the CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.

A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6574: Medicare Fair Drug Pricing Act of 2018. 115th Congress. Open America. https://openamerica.io/bill/115-HR-6574/
MLA
"H.R. 6574: Medicare Fair Drug Pricing Act of 2018." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-6574/.
Bluebook (legal)
H.R. 6574, 115th Cong. (2026), https://openamerica.io/bill/115-HR-6574/.
Markdown link
[H.R. 6574: Medicare Fair Drug Pricing Act of 2018](https://openamerica.io/bill/115-HR-6574/)
Report a problem